KRYS

Company Overview — What Does Krystal Biotech, Inc. Do?

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech, Inc. (KRYS) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Krish S. Krishnan and employs approximately 210 people. With a market capitalization of $7.6B, KRYS is one of the notable companies in the Healthcare sector.

Krystal Biotech, Inc. (KRYS) Stock Rating — Reduce (April 2026)

As of April 2026, Krystal Biotech, Inc. receives a Reduce rating with a composite score of 42.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.KRYS ranks #2,129 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Krystal Biotech, Inc. ranks #243 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KRYS Stock Price and 52-Week Range

Krystal Biotech, Inc. (KRYS) currently trades at $256.27. The stock lost $2.06 (0.8%) in the most recent trading session. The 52-week high for KRYS is $298.30, which means the stock is currently trading -14.1% from its annual peak. The 52-week low is $122.80, putting the stock 108.7% above its annual trough. Recent trading volume was 59K shares, suggesting relatively thin trading activity.

Is KRYS Overvalued or Undervalued? — Valuation Analysis

Krystal Biotech, Inc. (KRYS) carries a value factor score of 49/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 43.02x, compared to the Healthcare sector average of 23.63x — a premium of 82%. The price-to-book ratio stands at 6.37x, versus the sector average of 2.75x. The price-to-sales ratio is 21.24x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, KRYS trades at 55.79x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 44.16x.

Overall, KRYS's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Krystal Biotech, Inc. Profitability — ROE, Margins, and Quality Score

Krystal Biotech, Inc. (KRYS) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 14.8%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 13.5% versus the sector average of -33.1%.

On a margin basis, Krystal Biotech, Inc. reports gross margins of 94.1%, compared to 71.5% for the sector. The operating margin is 37.8% (sector: -66.1%). Net profit margin stands at 48.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 39.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KRYS Debt, Balance Sheet, and Financial Health

Krystal Biotech, Inc. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.95x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $393M.

KRYS has a beta of 0.75, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Krystal Biotech, Inc. is 60/100, reflecting average volatility within the normal range for its sector.

Krystal Biotech, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Krystal Biotech, Inc. reported revenue of $366M and earnings per share (EPS) of $7.08. Net income for the quarter was $181M. Gross margin was 94.1%. Operating income came in at $139M.

In FY 2025, Krystal Biotech, Inc. reported revenue of $389M and earnings per share (EPS) of $7.08. Net income for the quarter was $205M. Revenue grew 33.9% year-over-year compared to FY 2024. Operating income came in at $161M.

In Q3 2025, Krystal Biotech, Inc. reported revenue of $98M and earnings per share (EPS) of $2.74. Net income for the quarter was $79M. Revenue grew 16.6% year-over-year compared to Q3 2024. Operating income came in at $41M.

In Q2 2025, Krystal Biotech, Inc. reported revenue of $96M and earnings per share (EPS) of $1.33. Net income for the quarter was $38M. Revenue grew 36.6% year-over-year compared to Q2 2024. Operating income came in at $39M.

Over the past 8 quarters, Krystal Biotech, Inc. has demonstrated a growth trajectory, with revenue expanding from $70M to $366M. Investors analyzing KRYS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KRYS Dividend Yield and Income Analysis

Krystal Biotech, Inc. (KRYS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KRYS Momentum and Technical Analysis Profile

Krystal Biotech, Inc. (KRYS) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

KRYS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Krystal Biotech, Inc. (KRYS) ranks #243 out of 838 stocks based on the Blank Capital composite score. This places KRYS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KRYS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KRYS vs S&P 500 (SPY) comparison to assess how Krystal Biotech, Inc. stacks up against the broader market across all factor dimensions.

KRYS Next Earnings Date

No upcoming earnings date has been announced for Krystal Biotech, Inc. (KRYS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KRYS? — Investment Thesis Summary

The quantitative profile for Krystal Biotech, Inc. suggests caution. The quality score of 35/100 flags below-average profitability. Price momentum is positive at 63/100, suggesting the trend favors buyers. Low volatility (stability score 60/100) reduces downside risk.

In summary, Krystal Biotech, Inc. (KRYS) earns a Reduce rating with a composite score of 42.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KRYS stock.

Related Resources for KRYS Investors

Explore more research and tools: KRYS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KRYS head-to-head with peers: KRYS vs AZN, KRYS vs SLGL, KRYS vs VMD.